• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾脏病学中的治疗性血浆置换。其适用范围?

Therapeutic plasma exchange in nephrology. Where it applies?

作者信息

Alamartine Eric, Maillard Nicolas

机构信息

Service de Néphrologie Dialyse Transplantation Rénale, CHU Saint Etienne, GIMAP EA3064, Université Jean Monnet, Saint Etienne Lyon, France.

出版信息

Transfus Apher Sci. 2019 Jun;58(3):262-265. doi: 10.1016/j.transci.2019.04.010. Epub 2019 Apr 19.

DOI:10.1016/j.transci.2019.04.010
PMID:31029612
Abstract

Plasma exchange had been proposed to treat many kidney diseases. A few controlled studies, observational studies, and mechanistic evidence have specified the better indications, which are thrombotic microangiopathies, kidney transplantation and ANCA-associated vasculitides. Plasma removal can be realized by filtration, centrifugation, or immunoadsorption, with differences in efficacy, but these also impact on volume load and anticoagulation in patients with renal failure.

摘要

血浆置换已被提议用于治疗多种肾脏疾病。一些对照研究、观察性研究及机制性证据已明确了更好的适应证,即血栓性微血管病、肾移植及抗中性粒细胞胞浆抗体相关性血管炎。血浆去除可通过过滤、离心或免疫吸附实现,其疗效存在差异,但这些方法也会影响肾衰竭患者的容量负荷及抗凝情况。

相似文献

1
Therapeutic plasma exchange in nephrology. Where it applies?肾脏病学中的治疗性血浆置换。其适用范围?
Transfus Apher Sci. 2019 Jun;58(3):262-265. doi: 10.1016/j.transci.2019.04.010. Epub 2019 Apr 19.
2
Plasma exchange for kidney disease: what is the best evidence?用于治疗肾脏疾病的血浆置换:最佳证据是什么?
Adv Chronic Kidney Dis. 2014 Mar;21(2):217-27. doi: 10.1053/j.ackd.2014.01.008.
3
[Plasma exchange in nephrology: Indications and technique].[肾脏病学中的血浆置换:适应证与技术]
Nephrol Ther. 2017 Feb;13(1):43-55. doi: 10.1016/j.nephro.2016.12.002. Epub 2017 Jan 16.
4
Plasma exchange for renal disease: evidence and use 2011.2011年肾病血浆置换:证据与应用
J Clin Apher. 2012;27(3):112-6. doi: 10.1002/jca.21221. Epub 2012 Apr 25.
5
[Plasma exchange in nephrology].
Rev Med Suisse. 2023 Mar 1;19(816):406-410. doi: 10.53738/REVMED.2023.19.816.406.
6
Plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis--a 25-year perspective.抗中性粒细胞胞浆抗体相关血管炎中的血浆置换——25年回顾
Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i146-9. doi: 10.1093/ndt/gfv051. Epub 2015 Mar 13.
7
A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges.治疗性血浆置换中局部枸橼酸盐抗凝的新处方模式。
BMC Nephrol. 2017 Mar 1;18(1):81. doi: 10.1186/s12882-017-0494-9.
8
Authors' Reply: Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange.作者回复:血浆置换治疗抗中性粒细胞胞浆抗体相关性血管炎的肾脏组织病理学
J Am Soc Nephrol. 2022 Jun;33(6):1224-1225. doi: 10.1681/ASN.2022030269. Epub 2022 Apr 11.
9
Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis.抗中性粒细胞胞浆抗体相关肾血管炎患者血清C3浓度及血栓性微血管病组织学表现与预后的关系
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2143-51. doi: 10.2215/CJN.00120115. Epub 2015 Nov 5.
10
PEXIVAS: The End of Plasmapheresis for ANCA-Associated Vasculitis?PEXIVAS:抗中性粒细胞胞浆抗体相关性血管炎血浆置换治疗的终结?
Clin J Am Soc Nephrol. 2021 Feb 8;16(2):307-309. doi: 10.2215/CJN.10550620. Epub 2020 Sep 22.

引用本文的文献

1
Evaluation of the safety and feasibility of extracorporeal therapy: therapeutic plasma exchange in dogs - report of five cases.体外治疗的安全性和可行性评估:犬治疗性血浆置换——5例报告
BMC Vet Res. 2025 May 16;21(1):348. doi: 10.1186/s12917-025-04758-0.
2
Case report: Eculizumab plus obinutuzumab induction in a deceased donor kidney transplant recipient with DEAP-HUS.病例报告:在接受过 DEAP-HUS 治疗的死亡供体肾移植受者中,使用依库珠单抗联合奥滨尤妥珠单抗进行诱导治疗。
Front Immunol. 2022 Dec 14;13:1073808. doi: 10.3389/fimmu.2022.1073808. eCollection 2022.
3
Practice Patterns of Induction Therapy in Severe Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
重症抗中性粒细胞胞浆抗体相关性血管炎诱导治疗的实践模式
Kidney Int Rep. 2022 Sep 9;7(12):2704-2708. doi: 10.1016/j.ekir.2022.08.029. eCollection 2022 Dec.
4
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers.一项在中国健康志愿者中进行的 I 期研究评估了新型 FcRn 抑制剂 HBM9161 的安全性、耐受性、药代动力学和药效学。
Clin Transl Sci. 2021 Sep;14(5):1769-1779. doi: 10.1111/cts.13019. Epub 2021 Jul 16.